Skip to content


1 July 2016

As Australia goes to the polls this weekend, good health is on the agenda and so is CGM.

The bipartisan support for CGM (continuous glucose monitoring) means that regardless of the result, our Australian type 1 diabetes community are one step closer to having access to technology for those who would benefit. It’s a critical step in making CGM widely available and to realising the appetite for new health technologies.

While the promises of the Coalition and Labor are different, increasing availability of this life-saving technology reinforces the value of a healthy community for everyone. So why is it so important?

The value of CGM for people with type 1 diabetes comes with an ability for this technology to ‘talk’ to an insulin pump and proactively ensure therapy is delivered appropriately.

CGM promotes good glucose level control – critical because poor control can lead to serious and costly diabetes-related complications such as blindness, kidney failure, amputations, heart disease, strokes and possibly death.

The advantages of CGM in addition to traditional finger sticks and HbA1c testing are well documented. Research has shown that:

  • 60% of glucose lows may not be revealed with fingersticks alone.[i]
  • CGM identifies four times as many serious glucose incidents as self-monitoring of blood glucose (SMBG).[i]
  • CGM can significantly reduce HbA1c and has been shown to reduce HbA1c levels by up to 1% when compared with fingerstick testing alone.[ii]

Until now, CGM has not received Government support because there’s no established funding pathway for technology like it. Medical devices – such as CGM – that are not permanently implanted in the body fall into a ‘black hole’ because they don’t fit the established norm associated with technology used to treat chronic disease, i.e. that it’s permanently implanted.In an era when medical devices are going to continue to push these boundaries and as Medtronic endeavour to deliver therapies that provide therapeutic benefit in new ways, we recognise the current funding pathways for medical technology must be addressed. We want to see that medical technology is available to all people who will benefit – it will only be through improving appropriate access to these advances in healthcare that we will see real change in the management of chronic disease.To learn more about how CGM works with an insulin pump check out this infographic:

CGM Explained_Illustration

[i] Kaufman FR, et al. A pilot study of continuous glucose monitoring system. Diab Care. 2001:24:2030-2034

[ii] Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of Sensor-Augmented Insulin Pump Therapy in Insulin Dependant Diabetes NEJM. 2010;363(4):311-320

No comments yet

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: